Praxis' epilepsy pipeline takes center stage after Ulixacaltamide's Phase 3 futility. Key trials for vormatrigine and relutrigine set for 2025. See more on PRAX here.
Praxis Precision Medicines (PRAX) stock falls amid concerns over success in its late-stage trial for lead asset ulixacaltamide in essential tremor. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback